The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Subcutaneous
Route
3 recommended
Sites
Once weekly
Frequency
Preparation
Pre-filled tirzepatide single-dose pen (Mounjaro or Zepbound)—no mixing required
Alcohol swabs for injection site cleaning
Sharps container for safe pen disposal
Calendar or reminder app for weekly dosing
Pro tip
Prepare all supplies on a clean surface before you begin. Having everything ready makes the process smoother and more sterile.
Mixing
Example calculation
Tirzepatide comes in pre-filled, single-dose pens at specific strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg. Each pen contains exactly one dose—no calculations or dose selection needed. Simply use the entire pen contents for your weekly injection.
Dose calculation
Each pen is designed for single use at its labeled dose. For example, a 5mg pen delivers exactly 5mg when fully administered. The pen mechanism ensures you receive the complete dose. Use one pen per week at your prescribed strength.
Location
Site 01
Abdomen
Pinch the skin 2 inches from navel. Avoid the area directly around the belly button. Rotate between left and right sides.
Site 02
Outer Thigh
Middle third of the outer thigh. Keep at least 4 inches above the knee and below the hip. Alternate legs each injection.
Site 03
Upper Arm
Back or outer area of the upper arm. This site may require assistance from another person for proper technique.
Rotate between 3 sites to prevent tissue buildup and ensure consistent absorption.
Pro tip
Rotate your injection sites with each dose to prevent lipohypertrophy (buildup of fatty tissue). Keep a simple log of where you last injected.
Step by step
Remove pen cap and check the medicine window—solution should be clear and colorless
Clean your injection site with an alcohol swab and let it air dry completely
Remove the base cap to reveal the needle (it's hidden until you're ready)
Press the pen firmly against your skin at a 90-degree angle
Press and hold the purple injection button until you hear two clicks
Keep the pen pressed against your skin until the gray plunger is visible (about 5-10 seconds)
Remove the pen and dispose of the entire pen in a sharps container—each pen is single-use
Pro tip
This peptide uses subcutaneous injection (into the fatty tissue just under the skin)—the pen makes it quick and virtually painless, and you can easily do it yourself at home. Inject at a 45-90 degree angle into pinched skin. Aspirate before injecting to ensure you haven't hit a blood vessel.
Timing
Optimal timing
Best time
Pick any day of the week that works for you and stick with it. Many people choose a weekend day so they can rest if they experience mild nausea. The exact time of day doesn't matter much thanks to the long half-life—just be consistent [5][6].
With food?
Tirzepatide injections can be taken with or without food—it won't affect how the medication works. However, because it slows stomach emptying significantly, eating smaller meals will help you avoid nausea and discomfort. Avoid large, fatty meals.
Stacking notes
Tirzepatide is typically used as a standalone weight management therapy. If you have diabetes and take insulin or sulfonylureas, those doses will likely need to be reduced to prevent low blood sugar. [5][6] Always coordinate with your healthcare provider before combining medications.
Sample daily schedule
Same day each week (e.g., every Sunday morning)
As prescribed (2.5mg to 15mg depending on titration phase) injection
Site: Rotate between abdomen, thigh, and arm weekly
Pick a day you'll consistently remember—many people choose weekends so they can rest if needed. The injection takes under a minute once you're comfortable with it. If you miss a dose and it's been less than 4 days, take it as soon as you remember. If more than 4 days have passed, skip it and take your next dose on the regular day.
Dosing tiers
Dose
2.5 mg
Frequency
Once weekly
Duration
First 4 weeks
FDA label starting dose; non-therapeutic, used only to improve GI tolerability before escalating [5]. Inject in abdomen, thigh, or upper arm and rotate sites.
Dose
5-10 mg
Frequency
Once weekly
Duration
Increase by 2.5 mg after at least 4 weeks at each dose
Per FDA label, increase to 5 mg after 4 weeks; further increases in 2.5 mg steps no sooner than every 4 weeks as needed [5].
Preservation
Before mixing
Store new, unopened pens in the refrigerator at 36-46°F (2-8°C). Never freeze tirzepatide—freezing destroys the medication. Keep pens in the original carton to protect from light. If needed, unopened pens can be stored at room temperature (up to 86°F/30°C) for up to 21 days.
After mixing
Tirzepatide pens are single-use and do not require reconstitution. Once you use a pen, dispose of it properly in a sharps container. Never reuse pens or attempt to get multiple doses from one pen.
Shelf life after mixing
Single-use pen (discard after use)
Signs of degradation
Discard the vial immediately if you notice any of these:
Solution appears cloudy, discolored, or contains particles (should be clear and colorless)
Pen has been frozen or exposed to temperatures above 86°F (30°C) for extended periods
Solution looks yellow, brown, or has changed from its original appearance
Pen is damaged, cracked, or the mechanism doesn't click properly
Important
When to stop
Severe or persistent GI symptoms that prevent adequate nutrition despite dose adjustments and supportive care
Signs of pancreatitis—severe abdominal pain radiating to the back requiring emergency evaluation
Allergic reaction—rash, hives, itching, facial swelling, or difficulty breathing
Signs of thyroid problems—neck lump, persistent hoarseness, difficulty swallowing
Pregnancy or planning to become pregnant (stop at least 1 month before attempting conception)
Severe kidney problems or persistent dehydration from GI symptoms
Your healthcare provider recommends discontinuation for any reason
Tirzepatide is a prescription medication that should only be started, adjusted, or stopped under medical supervision. This information is for education only and does not replace professional medical advice. While stopping tirzepatide abruptly is generally safe, discuss any changes with your healthcare provider. Weight regain is common after discontinuation.
Clean technique checklist
Wash hands thoroughly with soap and water before handling supplies
Swab vial tops and injection site with alcohol and let dry
Never touch the needle tip or allow it to contact non-sterile surfaces
Use a new syringe and needle for each injection
Dispose of used sharps in a proper sharps container
Store reconstituted peptides according to the storage instructions above
Published research
Jastreboff AM, Aronne LJ, Ahmad NN, et al. · 2022
This landmark trial proved tirzepatide's extraordinary effectiveness for weight loss. Participants on the 15mg dose lost an average of 20.9% of their body weight over 72 weeks—about 52 pounds. Over half the participants lost more than 20% of their weight, results previously only achievable with surgery.
Frías JP, Davies MJ, Rosenstock J, et al. · 2021
Head-to-head comparison showed tirzepatide beat semaglutide at every dose level. The 15mg tirzepatide dose reduced HbA1c by 2.30 percentage points versus 1.86 with semaglutide. Weight loss was also significantly greater—5.5kg more weight lost with tirzepatide 15mg compared to semaglutide 1mg.
Wadden TA, Chao AM, Machineni S, et al. · 2023
For people who had already lost at least 5% of their weight through intensive lifestyle changes, adding tirzepatide produced an additional 18.4% weight loss over 72 weeks. Total weight loss from original starting weight exceeded 25% for many participants.
Wilson JM, Lin Y, Luo MJ, et al. · 2022
Comprehensive analysis showed tirzepatide improves virtually every cardiovascular risk factor: blood pressure dropped 6-9 mmHg, triglycerides fell 25%, LDL cholesterol decreased, and inflammatory markers improved significantly across all doses studied.
Eli Lilly and Company · 2025
Eli Lilly and Company · 2026
US label for the obesity and obstructive sleep apnea indications. Boxed warning for rodent thyroid C-cell tumors and contraindication in personal or family history of MTC or MEN 2. Dose escalation from 2.5 mg once weekly in 2.5 mg steps at intervals of at least 4 weeks, maximum 15 mg once weekly, any time of day with or without meals. Adverse reactions in the pooled weight-reduction trials (5/10/15 mg): nausea 25/29/28%, diarrhea 19/21/23%, vomiting 8/11/13%, hair loss 5/4/5%; cholelithiasis 1.1%, cholecystitis 0.7%, cholecystectomy 0.2%; adjudicated acute pancreatitis 0.2%. Hair loss and gallbladder events were associated with weight reduction. Elimination half-life approximately 5-6 days; tirzepatide delays gastric emptying, largest after the first dose.
Aronne LJ, Sattar N, Horn DB, et al. · 2024
After a 36-week open-label lead-in producing 20.9% mean weight reduction, participants switched to placebo regained 14.0% of body weight over the following 52 weeks, while those continuing tirzepatide lost a further 5.5%.
Look M, Dunn JP, Kushner RF, et al. · 2025
DXA substudy of 160 SURMOUNT-1 participants. At week 72 body weight fell 21.3%, fat mass 33.9% and lean mass 10.9% with tirzepatide. Of the body weight lost, approximately 75% was fat mass and 25% was lean mass, in both the tirzepatide and placebo groups.
Coskun T, Sloop KW, Loghin C, et al. · 2018
The discovery paper for tirzepatide. A fatty-acid-modified peptide with dual GIP and GLP-1 receptor agonist activity engineered for once-weekly subcutaneous dosing. In mice it reduced body weight and food intake significantly more than a GLP-1 receptor agonist. The most frequent human side effects in phase 1 were gastrointestinal (vomiting, nausea, decreased appetite, diarrhoea, abdominal distension), all dose-dependent.
Willard FS, Douros JD, Gabe MBN, et al. · 2020
Receptor occupancy analysis at clinically efficacious doses shows a greater degree of engagement at the GIP receptor than the GLP-1 receptor, an imbalanced mechanism of action. Tirzepatide mimics native GIP at the GIP receptor but is biased at the GLP-1 receptor toward cAMP generation over beta-arrestin recruitment, with weaker GLP-1 receptor internalisation.
Heise T, DeVries JH, Urva S, et al. · 2023
Secondary analysis of a randomised, double-blind study of tirzepatide 15 mg, semaglutide 1 mg and placebo at 28 weeks. Tirzepatide significantly reduced body weight versus both placebo and semaglutide with greater fat mass reduction, and significantly reduced appetite versus placebo.
Bjerre Knudsen L, Madsen LW, Andersen S, et al. · 2010
The GLP-1 receptor was localised to rodent thyroid C-cells, where agonists stimulated calcitonin release and C-cell hyperplasia. Humans and cynomolgus monkeys had low GLP-1 receptor expression in thyroid C-cells and agonists did not generate calcitonin release in primates, delineating species-specific differences in thyroid GLP-1 receptor expression and action.
Pasternak B, Wintzell V, Hviid A, et al. · 2024
Cohort of 145,410 GLP-1 receptor agonist users versus 291,667 DPP-4 inhibitor users across Denmark, Norway and Sweden, 2007-2021. GLP-1 receptor agonist use was not associated with an increased risk of thyroid cancer (hazard ratio 0.93, 95% CI 0.66 to 1.31) over a mean 3.9 years of follow-up; hazard ratio for medullary thyroid cancer 1.19 (0.37 to 3.86).
Zhang Q, Delessa CT, Augustin R, et al. · 2021
GIP receptors in hypothalamic feeding centres mediate control of food intake and body weight. Acyl-GIP increased cFos neuronal activity in hypothalamic feeding centres and lowered body weight and food intake in wild-type but not CNS-Gipr knockout mice, and the superior metabolic effect of GLP-1/GIP co-agonism over GLP-1 alone was extinguished in CNS-Gipr knockout mice.
Samms RJ, Christe ME, Collins KA, et al. · 2021
Tirzepatide improved insulin sensitivity in obese mice to a greater extent than GLP-1 receptor agonism, and did so in the absence of GLP-1R-mediated weight loss by enhancing glucose disposal in white adipose tissue. A long-acting GIP receptor agonist reproduced the effect, showing GIP receptor agonism contributes insulin sensitisation and adipose tissue glucose handling.
Eli Lilly and Company / ClinicalTrials.gov · 2020
Phase 3 cardiovascular outcomes trial of tirzepatide versus dulaglutide in 13,299 participants with type 2 diabetes and increased cardiovascular risk, assessing major adverse cardiovascular events. Started 29 May 2020.
He Z, Gao Y, Lieu L, et al. · 2019
GLP-1 receptor agonism directly activates arcuate POMC neurons and indirectly inhibits NPY/AgRP neurons through increased GABAergic inhibitory input, the two arcuate pathways through which GLP-1 receptor activation reduces food intake.
Head to head